Navigation Links
Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research
Date:10/12/2009

SAN FRANCISCO, Oct. 12 /PRNewswire/ -- Dr. Michael Merzenich, PhD - renowned neuroscientist, university professor, cochlear implant inventor, brain plasticity expert and tech entrepreneur - was formally inducted in the Institute of Medicine (IOM) today in Washington, D.C. Also a member of the National Academy of Sciences, Dr. Merzenich is one of a small group of scientists and doctors in the U.S. who have been selected for recognition by both institutions. IOM members are elected by their peers through a selective process that recognizes people who have made major contributions to the advancement of the medical sciences, health care, and public health.

"I am, of course, delighted by the generosity of my colleagues to be chosen for this honor," said Dr. Merzenich, currently co-founder and Chief Scientific Officer at Posit Science. "The discovery of the brain's ability to rewire itself has been at the core of my life's work, and I have been very fortunate to have worked with some of the brightest scientists, technologists and clinicians in the world with the mission of applying our science to improve the quality of life for others."

Dr. Merzenich is currently working with scientists and doctors at the University of California, San Francisco (UCSF) on mental health solutions, including recent promising studies on the use of brain fitness training conducted in aging, brain-injured, autistic and schizophrenic patient populations.

"Mike has been a pioneer and a leader in demonstrating that the brain function and wiring is sensitive to neural activity. His basic work has elucidated mechanisms underlying this plasticity, and his translational work has illuminated the possible ways medicine can intervene to ameliorate brain disorders," said Dr. John Rubenstein, MD, PhD, distinguished professor in Child Psychiatry at UCSF and an IOM member. "His work has revolutionized the way we view the brain's plasticity and his latest work in mental disorders illustrates his sincere dedication to alleviate human suffering."

For more than three decades, Dr. Merzenich has been a leading pioneer in brain plasticity research. In 1971, Dr. Merzenich joined the faculty of UCSF and started the Keck Center for Integrative Neurosciences. In the late 1980's, Dr. Merzenich was part of the team that invented the cochlear implant. In 1990 he became a full professor at UCSF in Neuroscience, Physiology, Biomedical Engineering and Otolaryngology. He is currently Professor Emeritus in the departments of Otolaryngology and Physiology at UCSF.

In 1996, Dr. Merzenich was the founding CEO of Scientific Learning Corporation, which markets and distributes software that applies principles of brain plasticity to assist children with language learning and reading. In 2003, Posit Science was begun by Dr. Merzenich and Jeff Zimman to take neuroscience out of the labs and put it into the hands of consumers with engaging adaptive brain fitness software.

Dr. Merzenich has published more than 200 articles, including many in leading peer-reviewed journals (such as Science and Nature), received numerous awards and prizes (including the Ipsen Prize, Zulch Prize, Thomas Alva Edison Patent Award and Purkinje Medal) and has been granted more than 50 patents for his work.

"Mike's work not only improves cognitive function across a wide array of disorders and conditions," said Zimman, Chairman of Posit Science. "Results from his studies have also been shown to significantly improve broad measures of overall health such as health-related quality-of-life and performance of everyday tasks."

Dr. Merzenich holds a BS in General Science from the University of Portland and a PhD in Physiology from Johns Hopkins University, with a Neuroscience fellowship from the University of Wisconsin at Madison. To read his blog, go to http://merzenich.positscience.com/.

About Posit Science

Posit Science is the leader in delivering clinically proven brain fitness software into the hands of consumers. The company combines breakthrough research and a focus on great customer experiences to create products that are engaging and help users think faster, focus better and remember more. Staff neuroscientists collaborate with more than 50 scientists from leading research institutions as well as engineers and product marketers to design, build and test our computer-based programs. Posit Science products are available online, through health, long term care and auto insurers, and from public television's "The Brain Fitness Program" documentary. For more information, visit www.PositScience.com or call 1-866-599-6463.

Posit Science is a registered trademark of Posit Science Corp. Other company and product names may be trademarks of their respective owners.

SOURCE Posit Science


'/>"/>
SOURCE Posit Science
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
11. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
Breaking Biology News(10 mins):